multitarget antifolate Search Results


multitarget antifolate  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals multitarget antifolate
<t> Gemcitabine </t> monotherapy versus fluorouracil monotherapy for non-resectable (locally advanced or advanced) pancreatic cancer
Multitarget Antifolate, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multitarget antifolate/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
multitarget antifolate - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
multitargeted antifolate mta  (AstraZeneca ltd)
90
AstraZeneca ltd multitargeted antifolate mta
<t> Gemcitabine </t> monotherapy versus fluorouracil monotherapy for non-resectable (locally advanced or advanced) pancreatic cancer
Multitargeted Antifolate Mta, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multitargeted antifolate mta/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
multitargeted antifolate mta - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Gemcitabine monotherapy versus fluorouracil monotherapy for non-resectable (locally advanced or advanced) pancreatic cancer

Journal: Clinical Evidence

Article Title: Pancreatic cancer

doi:

Figure Lengend Snippet: Gemcitabine monotherapy versus fluorouracil monotherapy for non-resectable (locally advanced or advanced) pancreatic cancer

Article Snippet: , , Subgroup analysis , Gemcitabine monotherapy v gemcitabine plus other cytotoxic agent (multitarget antifolate, pemetrexed, or topoisomerase inhibitors irinotecan or exatecan) , Overall survival: 4 RCTs, 1404 people; HR 0.99; P = 0.80; no further data reported.

Techniques:

Gemcitabine monotherapy versus gemcitabine-based combinations for non-resectable (locally advanced or advanced) pancreatic cancer

Journal: Clinical Evidence

Article Title: Pancreatic cancer

doi:

Figure Lengend Snippet: Gemcitabine monotherapy versus gemcitabine-based combinations for non-resectable (locally advanced or advanced) pancreatic cancer

Article Snippet: , , Subgroup analysis , Gemcitabine monotherapy v gemcitabine plus other cytotoxic agent (multitarget antifolate, pemetrexed, or topoisomerase inhibitors irinotecan or exatecan) , Overall survival: 4 RCTs, 1404 people; HR 0.99; P = 0.80; no further data reported.

Techniques: